Partial Versus Complete Bacillus Calmette-Guérin Intravesical Therapy and Bladder Cancer Outcomes in High-risk Non–muscle-invasive Bladder Cancer: Is NIMBUS the Full Story?
Open Access
- 16 February 2021
- journal article
- research article
- Published by Elsevier BV in European Urology Open Science
- Vol. 26, 35-43
- https://doi.org/10.1016/j.euros.2021.01.009
Abstract
No abstract availableFunding Information
- Health Services Research and Development
This publication has 25 references indexed in Scilit:
- EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016European Urology, 2016
- Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO GuidelineJournal of Urology, 2016
- Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer GroupJournal of Clinical Oncology, 2016
- Risk Adjustment Tools for Learning Health Systems: A Comparison of DxCG and CMS‐HCC V21Health Services Research, 2016
- EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-GuérinEuropean Urology, 2016
- Quality of care in patients with bladder cancerCancer, 2011
- History of Bacillus Calmette-Guerin and Bladder Cancer: An Immunotherapy Success StoryJournal of Urology, 2008
- Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC TrialsEuropean Urology, 2006
- Are Patients at Veterans Affairs Medical Centers Sicker?Archives of Internal Medicine, 2000
- What Is the Optimal Regimen for BCG Intravesical Therapy?European Urology, 2000